{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'LIST OF FIGURES', 'Figure 7.1 Thyroid Eye Disease Photographs', '52', 'Figure 9.1 Schematic of Study Design', '71', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 43 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '4', 'LIST OF ABBREVIATIONS', 'Abbreviation', 'Definition', 'A subscale', 'Appearance subscale of GO-QoL', 'ADA', 'Anti-drug antibody', 'AE', 'Adverse event', 'AESI', 'Adverse event of special interest', 'ALT', 'Alanine aminotransferase', 'APD', 'Afferent pupillary defect', 'AST', 'Aspartate aminotransferase', 'AUC', 'Area under the concentration-time curve', 'CAS', 'Clinical activity score', 'CFR', 'Code of Federal Regulations', 'CHO', 'Chinese hamster ovary', 'CL', 'Clearance', 'Cmax', 'Maximum observed concentration', 'CPI', 'Coordinating principal investigator', 'CRO', 'Contract research organization', 'CS', 'Clinically significant', 'Ctrough', 'Trough concentration', 'CV', 'Coefficient of variance', 'DSMB', 'Data safety monitoring board', 'EAA', 'European Economic Area', 'ECG', 'Electrocardiogram', 'EDC', 'Electronic data capture', 'eCRF', 'Electronic case report form', 'EOS', 'End-of-Study', 'EOT', 'ind-of-Treatment', 'EU', 'European Union', 'EUGOGO', \"European Group on Graves' Ophthalmopathy\", 'FDA', 'Food and Drug Administration', 'FT3', 'Free triiodothyronine', 'FT4', 'Free thyroxine', 'GCP', 'Good Clinical Practice', 'GD-IgG', \"Graves' disease immunoglobulin G\", 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 44 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'Abbreviation', 'Definition', 'GO', \"Graves' ophthalmopathy or orbitopathy\", 'GO-QoL', \"Graves' Ophthalmopathy Quality of Life\", 'HbA1c', 'Glycated hemoglobin', 'HIPAA', 'Health Insurance Portability and Accountability Act', 'HZN-001', 'Teprotumumab (previously RV 001)', 'IB', \"Investigator's brochure\", 'IBD', 'Inflammatory bowel disease', 'ICD', 'Intercanthal distance', 'ICF', 'Informed consent form', 'ICH', 'International Conference of Harmonization', 'IEC', 'Independent ethics committee', 'IGF-1R', 'Insulin-like growth factor-1 receptor', 'IL', 'Interleukin', 'IND', 'Investigational new drug', 'IRB', 'Institutional review board', 'ITT', 'Intent-to-treat', 'IV', 'Intravenous', 'IWRS', 'Interactive web response system', 'LR', 'Light reflex', 'mAb', 'Monoclonal antibody', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'NAb', 'Neutralizing antibody', 'NCI', 'National Cancer Institute', 'NCI-CTCAE', 'National Cancer Institute Common Terminology Criteria for Adverse Events', 'NCS', 'Not clinically significant', 'PBMC', 'Peripheral blood mononuclear cells', 'PD', 'Pharmacodynamic', 'PK', 'Pharmacokinetic', 'PopPK', 'Population pharmacokinetics', 'PVC', 'Polyvinyl chloride', 'PW', 'Premature withdrawal', 'q3W', 'Once every 3 weeks', 'QoL', 'Quality of life', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 45 of 118']\n\n###\n\n", "completion": "END"}